| __timestamp | Agios Pharmaceuticals, Inc. | Exelixis, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 50829000 |
| Thursday, January 1, 2015 | 35992000 | 57305000 |
| Friday, January 1, 2016 | 50714000 | 116145000 |
| Sunday, January 1, 2017 | 71124000 | 159362000 |
| Monday, January 1, 2018 | 114145000 | 206366000 |
| Tuesday, January 1, 2019 | 132034000 | 228244000 |
| Wednesday, January 1, 2020 | 149070000 | 293355000 |
| Friday, January 1, 2021 | 121445000 | 401715000 |
| Saturday, January 1, 2022 | 121673000 | 459856000 |
| Sunday, January 1, 2023 | 119903000 | 542705000 |
| Monday, January 1, 2024 | 156784000 | 492128000 |
Unleashing insights
In the competitive world of biotechnology, managing operational costs is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Exelixis, Inc. and Agios Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Exelixis consistently outpaced Agios in SG&A spending, with a notable increase of over 900% from 2014 to 2023. In contrast, Agios saw a more modest rise of approximately 525% in the same timeframe. This disparity highlights Exelixis's aggressive investment in administrative and sales functions, potentially fueling its growth strategy. Meanwhile, Agios's steadier approach may reflect a more conservative operational model. Understanding these trends offers valuable insights into each company's strategic priorities and market positioning.
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Exelixis, Inc.
Cost Management Insights: SG&A Expenses for Amgen Inc. and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Agios Pharmaceuticals, Inc.
Exelixis, Inc. or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and HUTCHMED (China) Limited
Comparing SG&A Expenses: Exelixis, Inc. vs Novavax, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and MiMedx Group, Inc.
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Vericel Corporation vs Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Geron Corporation
Agios Pharmaceuticals, Inc. vs Novavax, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Agios Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.